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Abstract
Insulin inhibits ischemia/reperfusion-induced myocardial apoptosis through the PI3K/Akt/
mTOR pathway. Survivin is a key regulator of anti-apoptosis against doxorubicin-induced
cardiotoxicity. Insulin increases survivin expression in cardiac myocytes to mediate cytopro-
tection. However, the mechanism by which survivin mediates the protective effect of insulin
against doxorubicin-associated injury remains to be determined. In this study, we demon-
strated that pretreatment of H9c2 cardiac myocytes with insulin resulted in a significant
decrease in doxorubicin-induced apoptotic cell death by reducing cytochrome c release
and caspase-3 activation. Doxorubicin-induced reduction of survivin mRNA and protein lev-
els was also significantly perturbed by insulin pretreatment. Reducing survivin expression
with survivin siRNA abrogated insulin-mediated inhibition of caspase-3 activation, suggest-
ing that insulin signals to survivin inhibited caspase-3 activation. Interestingly, pretreatment
of H9c2 cells with insulin or MG132, a proteasome inhibitor, inhibited doxorubicin-induced
degradation of the transcription factor Sp1. ChIP assay showed that pretreatment with insu-
lin inhibited doxorubicin-stimulated Sp1 dissociation from the survivin promoter. Finally
using pharmacological inhibitors of the PI3K pathway, we showed that insulin-mediated
activation of the PI3K/Akt/mTORC1 pathway prevented doxorubicin-induced proteasome-
mediated degradation of Sp1. Taken together, insulin pretreatment confers a protective
effect against doxorubicin-induced cardiotoxicity by promoting Sp1-mediated transactiva-
tion of survivin to inhibit apoptosis. Our study is the first to define a role for survivin in cellular
protection by insulin against doxorubicin-associated injury and show that Sp1 is a critical
factor in the transcriptional regulation of survivin.
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Introduction
Survivin (encoded by Birc5), a member of the inhibitor of apoptosis protein (IAP) family, plays
a crucial role in regulating apoptosis and contributes to tumor progression [1, 2]. Survivin sup-
presses mitochondrial apoptosis by inhibiting caspase-9 activities in concert with the caspase
inhibitor, XIAP [3].
Expression of the survivin gene is largely regulated at the transcription level [4]. The survi-
vin gene promoter region contains binding sites for numerous transcription factors, including
NF-κB, GATA-1, Stat3, E2F, c-myc, KLF5, DEC1, Sp1, Sp3, HIF-1α and tumor suppressors
p53 and Rb [1, 4–11]. Hoffman et al. reported that down-regulation of survivin transcription
by the DNA-damaging agent doxorubicin is mediated by p53 induction [12]. Other works
have shown that p53 suppresses survivin gene expression both directly and indirectly [4–6, 13,
14]. Conversely, it was demonstrated that Sp1 and Sp3 transcription factors transactivate the
survivin promoter [15].
Accumulated evidences have suggested that survivin is cardioprotective [16–18]. In the
spontaneously hypertensive rat, the survivin expression is inversely correlated with apoptosis
and adverse cardiac remodeling [19]. Cardiac-specific deletion of survivin results in premature
cardiac death due to a dramatic reduction in cardiac myocyte numbers [20]. In addition, survi-
vin is associated with cardiac myocyte size and DNA content in the failing human heart [21].
Doxorubicin, a quinine-containing anthracycline anticancer drug, is a highly effective che-
motherapeutic widely used against human hematological malignancies and solid tumors.
Although it has a strong anticancer effect, doxorubicin is also known to cause cardiotoxicity
that leads to hypotension, arrhythmia, depression of left ventricular function and heart failure
[22, 23]. A variety of studies have suggested the mechanism involved in doxorubicin-induced
cardiotoxicity and apoptosis, including reactive oxygen species (ROS) production, caspase acti-
vation and cell cycle arrest [24, 25]. The survivin gene therapy prevents myocytes from apopto-
sis and attenuates left ventricular systolic dysfunction in the doxorubicin-induced heart model
[26]. Recently, we also reported the protective effect of survivin against doxorubicin-induced
cell death in H9c2 cardiac myocytes [27]. The contribution of the phophatidylinositide-
3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) axis to survivin expression is
observed not only in various cancer cells [28, 29], but also in normal cells including cardiac
myocytes [30]. In the latter case, survivin plays a critical role in the cardioprotection of insulin
against myocardial ischemia/reperfusion (I/R) injury through the PI3K/Akt/mTOR signaling
pathway. However the contribution of the PI3K/Akt/mTOR pathway and survivin in insulin-
mediated protection of cardiac myocytes from doxorubicin-associated toxicity remains to be
determined. In this study, we set out to elucidate the mechanism by which insulin signals to




Insulin, human recombinant from Saccharomyses cerevisiae, was purchased from Sigma-
Aldrich. Doxorubicin was obtained from Tocris. Anti-survivin, anti-caspase-3 (cleaved form),
anti-phospho-p53 (Ser15), anti-phospho-Akt (Ser473), anti-Akt, anti-phospho-mTOR (Ser2481)
and anti-mTOR antibodies were obtained from Cell Signaling. Anti-Sp1, anti-phospho-
p70S6K (Thr421/Ser424), anti-p70S6K, anti-β-actin, anti-GAPDH, anti-Smac/DIABLO antibod-
ies and p70S6K inhibitor PF4708671 were purchased from Santa Cruz Biotechnology. Anti-
VDAC1, anti-p53, anti-Bcl-2, and anti-BAX antibodies were obtained from Abcam. PI3K
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inhibitor LY294002 and mTOR inhibitor Rapamycin were purchased from Calbiochem. Anti-
cytochrome c antibody was included in ApoAlert Cell Fractionation Kit (Clontech).
Cell culture
The rat heart-derived myoblast cell line H9c2 (2–1) cardiac myocytes, was obtained from the
American Type Culture Collection (ATCC CRL-1446). Cells were maintained in Dulbecco’s
modified Eagle’s medium (DMEM) supplement with 10% fetal bovine serum (FBS) and 100 U/
ml of penicillin and 100 μg/ml of streptomycin (Gibco) at 37°C in a humidified atmosphere
with 5% CO2. All experiments were performed using cells between 15 to 25 passage numbers.
After adaptation in DMEM containing 10% FBS for 24 h, cells were starved in DMEM contain-
ing 0.5% FBS for 24 h. After starvation, cells were pretreated with insulin in 0.5% FBS contain-
ing DMEM for 1 h prior to doxorubicin treatment for 24 h.
Cell viability and cell death assay
Cell viability was measured by MTT assay and cell death was determined by TUNEL assay
(Promega), cytochrome c release and caspase-3 activity assay (ApoAlert CPP32/caspase-3
assay kit, BD Biosciences), which were performed as described previously [27].
Confocal immunofluorescence microscopy
Immunofluorescence microscopy was performed as previously reported [27]. Briefly, H9c2
cells cultured on Lab-Tek chamber slides (Nalgene Nunc) were fixed with 3% paraformalde-
hyde and permeablized with 0.5% Triton X-100. After blocking with PBS containing 0.3% goat
serum and 5% bovine serum albumin, the slides were incubated with survivin antibody and
mounted with ProLongantifade reagent containing DAPI. The immunoreactive signals were
visualized by confocal laser scanning microscope LSM700 (Carl Zeiss, Germany).
Subcellular fractionation and Immunoblot analysis
Mitochondrial and cytosolic fractions were obtained using Qproteome Cell Compartment Kit
(Qiagen) according to the manufacturer's instructions, and protein sample preparation and
immunoblot analysis were performed as described previously [27].
Reverse transcription-polymerase chain reaction (RT-PCR)
Total RNA was isolated using QIAzol-Regent (Qiagen) and reverse transcribed using Omnis-
cript Reverse Transcriptase (Qiagen). The cDNAs were amplified using TaKaRa Ex Taq poly-
merase (Takara). The sequences of the primers were as follows: survivin F, 5'-ATG GGT GCT
ACG GCG CTG CCC-3'; survivin R, 5'-TCA GCG TAA GGC AGC CAG CTG-3'; Sp1 F, 5'-
GGA GAA AAC AGC CCA GGA TGC-3'; Sp1 R, 5'-CTC ATC CGA ACG TGT GAA GC-3';
GAPDH F, 5'-AAT GCA TCC TGC ACC ACC AAC TGC-3'; GAPDH R, 5'-GGA GGC CAT
GTA GGC CAT GAG GTC-3'. PCR products were separated by electrophoresis in a 1% agarose
gel containing Gel-red (Biotium).
RNA interference
H9c2 cells were transfected with scrambled RNA or siRNA targeted to either survivin or Sp1
gene using Lipofectamine RNA iMAX (Invitrogen) according to the manufacturer’s protocol.
survivin siRNA targeting sequences, 5'-GCA AAG GAG ACC AAC AAC AUU-3' and 5'-UGU
UGU UGG UCU CCU UUG CUU-3’, and Sp1 siRNA targeting sequences, 5'-AGC CUU GAA
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GUG UAG CUA UUU-3' and 5'-AUA GCU ACA CUU CAA GGC UUU-3' were synthesized by
Genolution Pharmaceuticals. Scrambled RNA was purchased from Santa Cruz Biotechnology.
Chromatin immunoprecipitation (ChIP)
ChIP assay was performed according to Hsu et al. with minor modifications [31]. Briefly, form-
aldehyde-treated nuclear lysates were subjected to immunoprecipitation with anti-Sp1 and
anti-p53 antibodies. The cross-linked chromatin complex was reversed in the presence of pro-
teinase K and DNA fragments were purified. The DNA fragment (257-bp) of survivin pro-
moter region (between -265 and -9) was amplified by PCR using a pair of primers: Rat survivin
promoter F, 5’-AGG ACA CAA CTC CCA GCA AG- 3’; Rat survivin promoter R, 5’-CGC
CAC AAT CCC TAA TTC AA- 3’. PCR condition was as follows: at 95°C for 30 sec; at 56°C for
30 sec; and at 72°C for 60 sec. After 36 cycles of PCR, products were analyzed by 2% agarose
gel electrophoresis. For input data (5%), 25 μl aliquots of 500 μl samples were taken before
immunoprecipitation.
Statistical analysis
Data were expressed as mean ±S.D. One-way ANOVA with Bonferroni post hoc correction
was used for comparison between the groups using the Prism software (GraphPad Software
Inc.). Values of p less than 0.05 were considered statistically significant.
Results
Insulin protects H9c2 cardiac myocytes from doxorubicin-induced cell
death
To investigate whether insulin protects H9c2 cardiac myocytes against doxorubicin-induced
injury, H9c2 cardiac myocytes were pretreated with insulin for 1 h prior to doxorubicin treat-
ment. Consistent with previous reports [27], stimulation of H9c2 cells with doxorubicin for 24
h, 48 h or 72 h reduced cell viability to 49.8 ± 0.4%, 24.9 ± 2.7% and 23.5 ± 2.0%, respectively
(Fig 1A). However, doxorubicin-stimulated cell death was significantly perturbed by pretreat-
ment with 200 nM of insulin resulting in 84.2 ± 0.8% of H9c2 cell viability (Fig 1B). Consis-
tently, doxorubicin treatment stimulated apoptosis in 90.0 ± 2.3% of H9c2 cells, and insulin
pretreatment dramatically reduced the doxorubicin-induced apoptotic cell death to
21.4 ± 2.0%, as determined by TUNEL assay (Fig 1C and 1D). Similar to the previous findings
[27], pretreatment with doxorubicin alone stimulated activation of other markers of apoptotic
cell death in H9c2 cells, including activation of caspase-3, release of pro-apoptotic mitochon-
drial proteins cytochrome c and Smac/DIABLO to cytosol, decreasing anti-apoptotic Bcl-2
protein levels and increasing pro-apoptotic Bax protein levels. However, pretreatment with
insulin prevented doxorubicin-stimulated caspase-3 activation (Fig 1E), release of cytochrome
c (Fig 1F) and Smac/DIABLO (S1A Fig), decreased Bcl-2 protein levels and increased Bax pro-
tein levels (S1B Fig). These results suggest that insulin protects H9c2 cardiac myocytes from
doxorubicin toxicity by blocking apoptosis.
Insulin inhibits the doxorubicin-induced survivin down-regulation in H9c2
cardiac myocytes
Previously Si et al. showed that insulin inhibits I/R-induced myocardial apoptosis by stimulat-
ing the survival signaling cascade PI3K/Akt/mTOR/survivin pathway [30]. Further, survivin
has been shown to be cardioprotective [16–18]. Thus, we examined whether survivin expres-
sion is altered by insulin stimuli in doxorubicin-associated injury. Insulin treatment alone did
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Fig 1. Protective effect of insulin on the doxorubicin-induced cell death in H9c2 cardiac myocytes. (A) H9c2 cardiac myocytes were left untreated or
treated with 1 μM doxorubicin (Doxo) for 24 h, 48 h, and 72 h. (B) Serum-deprived H9c2 cardiac myocytes were left untreated or pretreated with the indicated
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not affect survivin protein levels in H9c2 cells (p = 0.2, n = 8) (S2 Fig). Interestingly, H9c2 cells
treated with doxorubicin had reduced levels of survivin protein (Fig 2A and 2C) and mRNA
(Fig 2B), and these reductions were suppressed with insulin pretreatment. The role of survivin
in insulin-mediated H9c2 cell protection was investigated using the siRNA knockdown
method. H9c2 cardiac myocytes were transfected with the siRNA targeting survivin to reduce
its expression. Fig 2D shows the efficiency of survivin siRNA in reducing the protein level of
survivin. As shown in Fig 2E, the ability of insulin to suppress doxorubicin-mediated caspase-3
activation was completely perturbed by survivin knockdown (lane 4). These findings suggest
that survivin plays a pivotal role in the cytoprotection of insulin by blocking the doxorubicin-
induced apoptotic activity in H9c2 cardiac myocytes.
Insulin inhibits doxorubicin-induced up-regulation of p53 and down-
regulation of Sp1
The survivin gene promoter contains several Sp1 and p53 binding sites with some variations
between species, indicating the evolutionarily conserved participation of Sp1 and p53 in the
survivin gene regulation. We found that doxorubicin treatment reduced Sp1 protein levels in
time- (S3A Fig) and dose-dependent manners (Fig 3A). This correlates with doxorubicin-stim-
ulated decrease in survivin mRNA levels at 12 h (S3B Fig), followed by a decrease in survivin
protein levels at 18 h (S3A Fig) in response to doxorubicin treatment. Conversely, insulin treat-
ment alone significantly increased Sp1 protein by 34.8% (Fig 3B). The reduction of Sp1 protein
due to doxorubicin treatment was significantly prevented by pretreatment with insulin (Fig
3B). In contrast to its protein levels, the mRNA levels of Sp1 were unaffected by doxorubicin
treatment with or without insulin pretreatment (Fig 3D, 3E and S4 Fig). Similar to the findings
in various human cancer cell lines [12], doxorubicin treatment alone stimulated an increase in
phosphorylation of p53 at Ser15 and total p53 levels (S3A Fig). Interestingly, insulin pretreat-
ment diminished doxorubicin-stimulated increase in p53 phosphorylation at Ser15 and total
p53 protein levels (Fig 3C).
Doxorubicin-induced protein degradation of Sp1 is associated with
proteasome-mediated proteolysis
To test whether doxorubicin-stimulated decrease in Sp1 protein level relies on proteasome-
dependent protein degradation, we pretreated H9c2 cells with the proteasome inhibitor
MG132. Intriguingly, similar to insulin pretreatment (Fig 3B), the reduction of Sp1 protein lev-
els due to doxorubicin treatment was significantly prevented by pretreatment with MG132 (Fig
4A). Consistently, MG132 pretreatment also inhibited the doxorubicin-mediated down-regula-
tion of survivin in both protein and mRNA levels (Fig 4B and 4C, respectively). These data sug-
gest that doxorubicin treatment triggers degradation of Sp1 protein via proteasome-mediated
concentration of insulin (Ins) for 1 h prior to treatment with 1 μM doxorubicin (Doxo) for 24 h. Cell viability was assessed by the MTT assay (**p < 0.01;
***p < 0.001, n = 3 performed in triplicates). (C–F) Serum-deprived cells were left untreated or pretreated with insulin (200 nM) for 1 h prior to treatment with
doxorubicin (1 μM) for 24 h. (C) Represented images of the TUNEL assay (100×). Treated cells were incubated with TUNEL reaction mixture, followed by
staining with DAPI. (D) The TUNEL-stained cells were counted under fluorescence microscopy and presented as a bar graph (***p < 0.001, n = 3 performed
in triplicates). (E) Caspase-3 activity was determined by immunoblot analysis of active form of caspase-3. (F) Mitochondrial (Mito) and cytosolic (Cyto)
fractions were separated by SDS-PAGE gel and analyzed by immunoblotting with anti-cytochrome C (Cyt C) antibodies. GAPDH or β-actin bands show that
equal amounts of sample were loaded and VDAC1 is used as a loading control for mitochondrial fraction. Note that blots represent one of three independent
experiments. Values are mean ±S.D.
doi:10.1371/journal.pone.0135438.g001
Insulin Induces Sp1-Mediated Survivin Expression
PLOS ONE | DOI:10.1371/journal.pone.0135438 August 13, 2015 6 / 19
Fig 2. Inhibitory effect of insulin on the doxorubicin-induced survivin down-regulation. (A, B) Serum-deprived H9c2 cardiac myocytes were left
untreated or pretreated with 200 nM insulin (Ins) for 1 h and treated with 1 μM doxorubicin (Doxo) for 24 h. (A) Whole cell lysates were separated by
SDS-PAGE gel and analyzed by immunoblotting with anti-survivin antibody. Graph represents the mean ±S.D. of the normalized densitometric analysis of
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proteolysis to suppress survivin expression, and insulin pretreatment inhibits this process
through an unknown mechanism.
Insulin restores the transcriptional activity of Sp1
To identify the Sp1 and p53 binding sites on the rat survivin promoter, we aligned the 5’-flank-
ing region of the rat, mouse and human survivin gene (Fig 5A). Based on the alignment, we
predicted a maximum of nine Sp1 and Sp1-like sites and two p53 binding sites in the promoter
survivin protein levels from 8 independent experiments (***p < 0.001, n = 8). (B) Total RNA was analyzed by RT-PCR (28 cycles) using primers specific to
survivin gene. Graph represents the mean ±S.D. of the normalized densitometric analysis of survivinmRNA levels from 3 independent experiments
(***p < 0.001, n = 3). (C) Immunofluorescence microscopy images were obtained using anti-survivin antibody followed by staining with DAPI (200×). (D, E)
One day after transfection with either scrambled RNA (scRNA) or survivin siRNA (20 nM), H9c2 cardiac myocytes were left untreated or pretreated with
insulin (200 nM) for 1 h and treated with doxorubicin (1 μM) for 24 h. Whole cell lysates were blotted with antibodies against survivin and cleaved-caspase-3
(active form). Note that the blots in panel D and E represent one of three independent experiments. n.s. not significant.
doi:10.1371/journal.pone.0135438.g002
Fig 3. Effect of insulin on the doxorubicin-induced changes in Sp1 and p53. (A, D) H9c2 cardiac myocytes were left untreated or treated with the
indicated concentration of doxorubicin (Doxo) for 12 h, and (B, C, E) serum-deprived cells were left untreated or pretreated with insulin (200 nM) for 1 h prior
to treatment with doxorubicin (1 μM) for 12 h. Whole cell lysates were analyzed by immunoblotting with anti-Sp1, anti-phospho-p53 (Ser15), anti-p53 and anti-
GAPDH antibodies. Graphs represent the mean ±S.D. of the normalized densitometric analyses of Sp1 protein levels (A, **p < 0.01, n = 3; B, ***p < 0.001,
n = 5). (D, E) Sp1 mRNA amount was determined by RT-PCR (28 cycles). Note that the blots in panel C represent one of three independent experiments.
doi:10.1371/journal.pone.0135438.g003
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region (between -265 and -9) of the rat survivin gene. To determine whether pretreatment with
insulin alters doxorubicin-stimulated binding of Sp1 and/or p53 to the survivin promoter, we
performed ChIP experiments using H9c2 cardiac myocytes. The fixed cell extracts were incu-
bated with anti-Sp1 or anti-p53 antibodies. The DNA-protein (promoter-transcription factor)
complexes captured by the antibodies were amplified by PCR to detect the presence of the sur-
vivin promoter. If Sp1 or p53 is bound to the survivin promoter, anti-Sp1 or anti-p53 antibod-
ies will be able to pull down the survivin promoter. Data presented in Fig 5B demonstrated that
in the absence of both doxorubicin and insulin, the survivin promoter was occupied by Sp1,
but not by p53. Following doxorubicin treatment of the H9c2 cardiac myocytes, the survivin
promoter had reduced levels of bound Sp1, but had increased level of bound p53. This observa-
tion is in accordance with the findings of Esteve et al. using human HCT116 cell line (doxoru-
bicin treatment) [13] and recently Hsu et al. using rat C6 glioma cell line (trichostatin A
treatment) [31]. However, when H9c2 cardiac myocytes were pretreated with insulin prior to
doxorubicin treatment, Sp1 binding to the survivin promoter was maintained while p53 bind-
ing to the survivin promoter was prevented by insulin.
To test whether Sp1 is a critical player in the insulin-induced survivin-mediated H9c2 cell
protection, H9c2 cells were transfected with the Sp1 siRNA to reduce Sp1 expression. The
effectiveness of the knockdown is shown in Fig 5C. As shown in Fig 5D and 5E, when Sp1
expression was reduced by siRNA, both survivinmRNA and its gene product, respectively,
were substantially reduced. Similar to the effect of survivin knockdown (Fig 2E, lane 4), insu-
lin-mediated suppression of doxorubicin-stimulated caspase-3 activation was also perturbed
Fig 4. Doxorubicin-induced Sp1 degradation by proteasome-mediated proteolysis. (A–C) H9c2 cardiac myocytes were pretreated with proteasome
inhibitor MG132 (50 nM) for 1 h and treated with 1 μM doxorubicin (Doxo) for either 12 h (A) or 24 h (B, C). (A, B) Whole cell lysates were analyzed by
immunoblotting using anti-Sp1 and anti-survivin antibodies. Graphs represent the mean ±S.D. of the normalized densitometric analyses of Sp1 (A, n = 5) or
survivin (B, n = 5) protein levels (***p < 0.001). (C) Total RNA was analyzed by RT-PCR (28 cycles) with specific primers to survivin gene. Graph represents
the mean ±S.D. of the normalized densitometric analysis of survivinmRNA levels (**p < 0.01; ***p < 0.001, n = 3).
doi:10.1371/journal.pone.0135438.g004
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Fig 5. Effect of doxorubicin and/or insulin on the transcriptional activity of Sp1 and p53. (A) Multiple sequence alignment (ClustalW2) of the proximal
promoter regions of the rat, mouse and human survivin genes. Black arrow indicates the transcriptional start site and +1 points out the translation start codon.
Canonical p53, Sp1, Sp1-like sites of the mouse and human survivin genes are boxed [12, 38–40]. Two gray bars indicate the primers for ChIP analysis [31];
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by reduction of Sp1 expression with Sp1 siRNA (lane 4). These evidences suggest that insulin
protects H9c2 cardiac myocytes from doxorubicin-induced apoptosis by blocking the protea-
some-mediated degradation of Sp1 resulting in Sp1-mediated transactivation of survivin.
Insulin inhibits Sp1 degradation via activation of the PI3K/mTORC1/
p70S6K pathway
Insulin-elicited cardiovascular protection is mediated by activation of PI3K/Akt/mTOR path-
way [32–36]. First, we determined whether insulin signals to the PI3K/mTOR/p70S6K pathway
to mediate cytoprotection against doxorubicin-mediated cell death. The results shown in
Fig 6A domonstrated that doxorubicin treatment of H9c2 cardiac myocytes reduced the phos-
phorylation levels of Akt (downstream target of PI3K), mTORC1 and p70S6K. However, when
the cells were pretreated with insulin, doxorubicin-mediated suppression of Akt, mTORC1
and p70S6K activation was perturbed. To determine the role of PI3K, mTOR and p70S6K in
mediating the inhibitory effect of insulin on the Sp1 degradation stimulated by doxorubicin,
three inhibitors were used; PI3K inhibitor LY294002, mTORC1 inhibitor rapamycin, and
p70S6K inhibitor PF4708671. As shown in Fig 6B to 6D, insulin-stimulated phosphorylation
of Akt, mTORC1, and p70S6K was inhibited by LY294002 (Fig 6B), rapamycin (Fig 6C), and
PF4708671 (Fig 6C), respectively. Pretreatment with LY294002, rapamycin, and PF4708671
blocked the ability of insulin to inhibit doxorubicin-induced Sp1 degradation (Fig 6B to 6D,
lane 6). It should be pointed out that pretreatment with LY294002, rapamycin, and PF4708671
did not affect total Akt, mTORC1, p70S6K or Sp1 protein levels (Fig 6B to 6D, lane 2).
Insulin protects H9c2 cardiac myocytes from doxorubicin toxicity by
Sp1-mediated transactivation of survivin via the PI3K/mTORC1/p70S6K
pathway
As shown in Fig 7A, pretreatment with LY294002, rapamycin, and PF4708671 also blocked the
ability of insulin to inhibit doxorubicin-induced survivin down-regulation (lane 4–6). Finally,
we investigated the effect of either survivin or Sp1 knockdown, or pharmacological inhibition
of the PI3K/mTOR/p70S6K pathway on the insulin-induced protection of H9c2 cardiac myo-
cytes. Consistent with the result shown in Figs 2E and 5D, doxorubicin treatment reduced cell
viability and this was perturbed with insulin pretreatment. Interestingly, the viability of cells
transfected with survivin siRNA (60.3 ± 3.2%) or Sp1 siRNA (60.1 ± 3.4%), or pretreated with
PI3K inhibitor (54.1 ± 6.3%), mTORC1 inhibitor (53.3 ± 3.8%), or p70S6K inhibitor
(61.8 ± 1.4%) prior to doxorubicin stimulation were similar to that of doxorubicin only-treated
group (52.1 ± 5.8%) (Fig 7B). These findings demonstrated that insulin-stimulated activation
of PI3K/mTORC1/p70S6K and expressions of Sp1 and survivin are required for insulin-medi-
ated protection against doxorubicin-stimulated cell death of cardiac myocytes.
a red bar corresponds to human CHR sequences; two blue bars highlight human CDE regions [50]. (B) Serum-deprived cells were left untreated or
pretreated with 200 nM insulin (Ins) for 1 h and treated with 1 μM doxorubicin (Doxo) for 12 h. Cross-linked cell lysates were subjected to ChIP analysis with
anti-Sp1 or anti p53-antibody. RT-PCR (36 cycles) was performed with ChIP primers as listed in Materials and Methods (n = 5). (C–E) One day after
transfection with Sp1 siRNA (20 nM), cells were left untreated or pretreated with insulin (200 nM) for 1 h and treated with doxorubicin (1 μM) for 24 h. Whole
cell lysates were immunoblotted with anti-Sp1, anti-survivin and anti-caspase-3 (active form) antibodies (C, D), and total RNA was analyzed by RT-PCR (28
cycles) with specific primers to survivin gene (E). Note that these results represent one of three independent experiments.
doi:10.1371/journal.pone.0135438.g005
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Fig 6. Inhibitory effect of insulin on the doxorubicin-induced Sp1 degradation via PI3K/Akt/mTORC1 pathway in H9c2 cardiac myocytes. (A)
Serum-deprived H9c2 cardiac myocytes were left untreated or pretreated with 200 nM insulin (Ins) for 1 h and treated with 1 μM doxorubicin (Doxo) for 12 h.
(B–D) Cells were pretreated with 2 μMPI3K inhibitor LY294002 (LY) (B), 1 μMmTORC1 inhibitor rapamycin (Rapa) (C), or 5 μM p70S6K inhibitor PF4708671
(PF). (D) for 1 h, followed by treatment with insulin (200 nM) for 1 h and then with doxorubicin (1 μM) for 12 h. Whole cell lysates were analyzed by
immunoblotting for protein levels or phosphorylation status of Akt, mTORC1 and p70S6K and for protein levels of Sp1 using antibodies listed in Materials and
Methods. Note that these blots represent one of three independent experiments. Graphs represent the mean ±S.D. of the normalized densitometric analyses
of Sp1 protein levels (*p < 0.05; **p < 0.01; ***p < 0.001, n = 3).
doi:10.1371/journal.pone.0135438.g006
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Discussion
The major findings of this study are as follows: First, Sp1 was down-regulated following doxo-
rubicin treatment, possibly by proteasome-mediated proteolysis. Insulin pretreatment blocked
doxorubicin-mediated Sp1 degradation by activating the survival signaling cascade PI3K/Akt/
mTORC1 pathway. In addition, reducing Sp1 expression with Sp1 knockdown successfully
blunted the insulin-induced cytoprotection. Second, our ChIP assay revealed that insulin pre-
treatment perturbed doxorubicin-mediated inhibition of the association of the transcription
factor Sp1 with the survivin gene promoter region (between -265 and -9). Conversely, insulin
Fig 7. Survivin-mediated protective effect of insulin on the doxorubicin-induced cardiac cell death. After pretreatment with the indicated inhibitors for
1 h (A, B), or transfection with either survivin siRNA or Sp1 siRNA for 24 h (B), cells were left untreated or treated with insulin (Ins) for 1 h, followed by
doxorubicin (Doxo) for 24 h. (A) Whole cell lysates were immunoblotted with anti-survivin antibodies. Numbers represent the mean ±S.D. of the normalized
densitometric analyses of survivin protein levels (n = 4). (B) Cell viability was assessed by the MTT assay (n = 3 performed in triplicates). Values are mean
±S.D. (*p < 0.05; **p < 0.01; ***p < 0.001). (C) Schematic diagram of insulin-induced cardiac myocytes protection against doxorubicin toxicity. Pro-
apoptotic signaling cascades induced by doxorubicin are shown as black lines and pro-survival (or anti-apoptotic) signaling pathways induced by insulin are
shown as red lines. (+) indicates positive transcriptional regulator (e.g. activator); (-) indicates negative transcriptional regulator (e.g. repressor).
doi:10.1371/journal.pone.0135438.g007
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pretreatment perturbed doxorubicin-stimulated p53 expression and phosphorylation at Ser15.
Consistently, our ChIP assay showed that doxorubicin-stimulated binding of p53 to the survi-
vin gene promoter was completely suppressed by insulin pretreatment.
Since Altieri and his colleagues reported survivin as a novel anti-apoptosis gene expressed
in cancer and lymphoma [37], the promoter region of survivin gene has been studied exclu-
sively in various cancer cell lines, mostly originated from mouse or human [12, 38–40]. In this
study, we investigated the regulation of survivin gene expression by Sp1 in mediating insulin-
stimulated protection against doxorubicin-mediated toxicity of H9c2 cells, a rat-derived non-
cancerous myoblast cell line. Changes in gene expression of Sp1 following doxorubicin is con-
troversial. In human colon carcinoma HCT116 cell line, Sp1 expression is not affected by
doxorubicin treatment, however p53 protein is markedly increased in the same condition [13,
41]. Doxorubicin treatment up-regulates Sp1 protein and mRNA levels in the human breast
adenocarcinoma MCF-7 [42] and chronic myeloid leukemic cell line K562 cells, respectively
[43]. In contrast, similar to our results, doxorubicin induces Sp1 down-regulation in doxorubi-
cin-resistant MCF-7 (MCF-7/Dox) cell line, whereas Sp1 mRNA is unchanged by doxorubicin
treatment [44]. Although Sp1 is believed to be a transcriptional activator, its possible role as a
transcriptional repressor in the survivin gene regulation also has been proposed. Inconsistent
with our ChIP data, in which Sp1 acted as a transcriptional activator, p53 appears on the pro-
moter without the loss of Sp1 to mediate dual function of both transcription activator and
repressor after 9 h of doxorubicin treatment [13].
The increased level of p53 protein can be accomplished by enhancing protein stability
instead of inducing transcription or translation. Our results supported the notion that DNA
damage, e.g. doxorubicin stimuli, induces phosphorylation of p53 at Ser15 and leads to a
reduced interaction between p53 and its negative regulator, the oncoprotein MDM2, which
inhibits p53 accumulation by targeting it for ubiquitination and proteasomal degradation [45,
46]. Surprisingly, the increase in the phosphorylation of p53 at Ser15 was reduced in H9c2 car-
diac myocytes that were pretreated with insulin. To better understand the mechanisms for
cytoprotection mediated by insulin, more studies will be required to identify the specific
kinases that are activated by doxorubicin to mediate the Ser15 phosphorylation and define the
precise correlation between the post-translational modification (phosphorylation or acetyla-
tion) of p53 and its function as transcription factor [13, 47]. Chromatin modification in the
promoter region may play a crucial role in the survivin gene silencing by p53 [6].
As shown in Fig 4, we designed an experiment using a potent proteasome inhibitor MG132
to inhibit doxorubicin-stimulated degradation of the Sp1 protein. Our findings are supported
by a recent publication that showed MG132 pretreatment of MCF-7/Dox cells inhibits the
doxorubicin-induced Sp1 down-regulation (the level of mRNA is not changed) [44]. Moreover,
inhibitor studies shown in Fig 6 demonstrated a connection between the mTOR pathway and
proteasome-mediated protein degradation [48]. We cannot exclude the possibility that another
signaling pathway might be involved in the insulin-induced inhibition of Sp1 degradation. As
shown in Fig 6, the efficiencies of the three inhibitors (LY294002> rapamycin> PF4708671)
suggested that a pathway might share the upstream kinases, PI3K, Akt and mTORC1, but they
might have distinct downstream mediators. Insulin-like growth factor-I (IGF-I) induces the
expression of survivin by increasing the translation of mRNA through mTOR-dependent
p70S6K activation, rather than by regulating gene transcription or protein stability [28, 49]. In
a more complicated study by Song et al., IGF-I reverses suppression of survivin gene expression
by TGF-β [49], whose survivin gene down-regulation depends on two cell cycle repressor ele-
ments in the survivin promoter region, a cell cycle-dependent element (CDE) and a cell cycle
genes homology region (CHR); and two transcription factors Smad2 and Smad3 [50].
Although it has been suggested that survivin plays a critical role in the cardioprotective effect
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of insulin through the activation of a survival cascade [30], the mechanism how insulin-elicited
activation of the PI3K/mTORC1/p70S6K pathway regulates survivin gene transcription
remains to be elucidated. In this study, it was successfully confirmed by ChIP assays that insu-
lin could reverse the doxorubicin-induced survivin down-regulation by maintaining the posi-
tive regulator Sp1 [51] on the promoter of survivin gene and removing the negative regulator
p53 [6] from the promoter of survivin gene.
Clinically, the doxorubicin-induced cardiotoxicity is one of the most important sequelae of
current chemotherapy against various cancers. A safe and effective method for reducing
anthracyclin-induced cardiotoxicity remains elusive [52]. In this study, we tested whether the
physiologic concentration of insulin could limit the doxorubicin-induced cardiotoxicity.
Recently, insulin-like growth factor (IGF) and its binding protein (IGFBP) involve in cancer
development, progression and anti-cancer drug resistance, thus IGF/IGFBP is an emerging tar-
get of cancer therapy [53, 54]. In line with these findings, insulin could be harmful in cancer
patients. Additionally, insulin may be beneficial by reducing host nutritional toxicity and result
in improvement of antitumor efficacy [55]. Therefore, further research should be warranted to
assess the clinical feasibility of insulin in cancer patients.
Taken together, our results support the hypothesis (a simplified scheme depicted in Fig 7C)
that i) insulin prevents Sp1 from the doxorubicin-induced proteasomal degradation via the
PI3K/mTORC1/p70S6K pathway; ii) the preserved Sp1 level by insulin transactivates the survi-
vin gene by direct binding to its promoter region; and iii) survivin mediates protective effect of
insulin against doxorubicin toxicity.
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S1 Fig. Effect of insulin on release of Smac/DIABLO and Bcl-2 family. (A, B) Serum-
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doxorubicin (1 μM) for 24 h. (A) Mitochondrial (Mito) and cytosolic (Cyto) fractions were sep-
arated by SDS-PAGE gel and analyzed by immunoblotting with anti-Smac/DIABLO antibod-
ies. (B) Whole cell lysates were immunoblotted with anti-Bcl-2, anti-BAX and anti-caspase-3
(active form) antibodies. VDAC1 and β-actin are used as a loading control for mitochondrial
and cytosolic fractions, respectively. Note that blots represent one of three independent experi-
ments.
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S2 Fig. Effect of doxorubicin and/or insulin on survivin expression at protein levels in
H9c2 cardiac myocytes. Eight replicates of Western blot for survivin. Whole cell lysates were
separated by SDS-PAGE gel and analyzed by immunoblotting with antibodies against survivin
and GAPDH.
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rubicin (Doxo) up to 1 μM for 12 h, and (B) cells were pretreated with insulin (200 nM) for 1 h
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